Article in The Journal of cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Guus A FrankenDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0009-0008-0905-6373
Harry Warner *Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-2313-6974
Jorge Cuenca-Escalona *Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-4915-1518
Isabel F StehleDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0009-0006-0957-5144
Vince P A van ReijmersdalDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0009-0005-2734-8247
Sophie E KlompDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0009-0009-0918-9093
Koert SchreursData Science, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands.ORCID 0009-0002-8573-868X
Andrea Rodgers-FuronesDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-0635-4470
Rohit Rajesh GokhaleDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0009-0007-3051-6568
Manon VullingsDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-9557-0406
René ClassensDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0009-0004-0143-6030
Stefania Di BlasioDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-7585-8277
Yusuf DolenDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0001-8211-9811
Sjoerd van DeventerDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0001-8972-6665
Katarina WolfDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-0616-2708
Inge M N WortelDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-3362-5229
Joseph H R HetmanskiDepartment of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University of London, London, UK.ORCID 0000-0002-1493-351X
Annemiek B van SprielDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-3590-2368
Laia Querol CanoDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-7650-9407
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Functional Proteomics by Reverse Phase Protein Array in CancerR50CA221675 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, YILING · 2017 to 2021
$726k
Dutch Cancer Society 11618Dutch Cancer Society 12949European Research Council 101112687European Research Council 724281Institute of Chemical Immunology ICI 000-23National Gaucher Foundation 1607.22.020NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS R50 CA221675Netherlands Organization for Scientific ResearchNIH HHS R50CA221675The University of Texas MD Anderson Cancer Center P30CA016672The University of Texas MD Anderson Cancer Center R50CA221675ZonMw 09120012010023
6 · The paper itself
Abstract
Adaptive immunity relies on dendritic cell (DC) migration to transport antigens from tissues to lymph nodes. Galectins, a family of β-galactoside-binding proteins, control cell membrane organization, exerting crucial roles in multiple physiological processes. Here, we report a novel mechanism underlying cell polarity and uropod retraction by demonstrating that galectin-9 regulates basal and chemokine-driven DC migration in humans and mice. Galectin-9 depletion caused a defect in RhoA signaling that resulted in impaired cell rear contractility. Mechanistically, galectin-9 interacts with and organizes CD44 at the cell surface, in turn modulating RhoA binding to GEF-H1 and the initiation of downstream signaling. Analysis of DC motility in the 3D tumor microenvironment revealed galectin-9 is also required for DC recruitment and infiltration. Exogenous galectin-9 rescued the motility of tumor-immunocompromised human blood DCs, validating the physiological relevance of galectin-9 in DC migration. Our results identify galectin-9 as a necessary mechanistic component for DC motility by regulating cell polarity and contractility, and underscore its implications for DC-based immunotherapies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Galectin-9 regulates dendritic cell polarity and uropod contraction by modulating RhoA activity. · full record | OpenQuestion